Bicocca Open Archive

Logo unimib boa
CIARDULLO, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.464
AS - Asia 5.839
EU - Europa 3.869
SA - Sud America 991
AF - Africa 184
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 2
Totale 17.386
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.014
SG - Singapore 2.097
IT - Italia 1.375
CN - Cina 1.128
HK - Hong Kong 758
BR - Brasile 734
VN - Vietnam 711
RU - Federazione Russa 616
DE - Germania 459
CA - Canada 369
SE - Svezia 306
IE - Irlanda 267
BD - Bangladesh 241
IN - India 196
GB - Regno Unito 194
FR - Francia 160
KR - Corea 126
ID - Indonesia 107
AR - Argentina 105
NL - Olanda 87
FI - Finlandia 77
IQ - Iraq 77
TR - Turchia 54
ZA - Sudafrica 54
JP - Giappone 53
CH - Svizzera 49
PK - Pakistan 49
UA - Ucraina 47
MX - Messico 45
ES - Italia 44
PL - Polonia 42
SA - Arabia Saudita 42
EC - Ecuador 39
AU - Australia 35
PH - Filippine 34
CO - Colombia 33
EG - Egitto 33
AT - Austria 31
VE - Venezuela 23
UZ - Uzbekistan 22
BE - Belgio 21
MA - Marocco 18
DK - Danimarca 16
JO - Giordania 16
TW - Taiwan 15
IR - Iran 14
MY - Malesia 14
PY - Paraguay 14
CL - Cile 13
DZ - Algeria 13
AE - Emirati Arabi Uniti 12
PT - Portogallo 12
RO - Romania 12
KE - Kenya 11
OM - Oman 11
NP - Nepal 10
PE - Perù 10
UY - Uruguay 10
TH - Thailandia 9
BG - Bulgaria 8
BO - Bolivia 8
CZ - Repubblica Ceca 8
ET - Etiopia 8
LT - Lituania 8
NG - Nigeria 8
PA - Panama 8
TN - Tunisia 7
AZ - Azerbaigian 6
IL - Israele 6
KZ - Kazakistan 6
SN - Senegal 6
CR - Costa Rica 5
DO - Repubblica Dominicana 5
GR - Grecia 5
AL - Albania 4
BY - Bielorussia 4
LB - Libano 4
NI - Nicaragua 4
PS - Palestinian Territory 4
ZM - Zambia 4
AO - Angola 3
BW - Botswana 3
GT - Guatemala 3
HN - Honduras 3
HR - Croazia 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
NO - Norvegia 3
ZW - Zimbabwe 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CY - Cipro 2
GD - Grenada 2
HU - Ungheria 2
JM - Giamaica 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
RS - Serbia 2
SC - Seychelles 2
SO - Somalia 2
Totale 17.359
Salva come PNG Salva come JPEG
Città #
Singapore 1.203
Hong Kong 732
Ann Arbor 702
Ashburn 589
San Jose 482
Milan 409
Santa Clara 316
Frankfurt am Main 286
New York 269
Chicago 257
Dublin 256
Toronto 251
Hefei 238
Ho Chi Minh City 209
Beijing 202
Chandler 201
Los Angeles 183
Fairfield 175
Dallas 171
Hanoi 157
Rome 106
Seoul 105
The Dalles 103
Wilmington 103
Princeton 96
Lauterbourg 86
Houston 82
Seattle 81
Boardman 75
Jakarta 71
Woodbridge 71
Cambridge 68
London 66
São Paulo 62
Council Bluffs 60
Altamura 58
Moscow 57
Munich 53
Shanghai 52
Buffalo 51
Helsinki 48
Lawrence 47
Zurich 44
San Diego 38
Orem 36
Montreal 35
Atlanta 34
San Francisco 33
Da Nang 32
Baghdad 31
Bari 31
Haiphong 30
Tokyo 28
Brooklyn 26
Warsaw 26
Dong Ket 24
Guangzhou 24
Monza 24
Nuremberg 24
Phoenix 23
Denver 22
Rio de Janeiro 22
Biên Hòa 20
Nanjing 20
Riyadh 20
Tashkent 20
Boston 19
Kent 19
Naples 19
Hải Dương 18
Johannesburg 18
Lappeenranta 18
Mumbai 18
Quito 18
Brussels 17
Dhaka 17
Figino 17
Stockholm 17
Bologna 16
Chennai 16
Turin 16
Kocaeli 15
Porto Alegre 15
Pune 15
Sydney 15
Vienna 15
Amman 14
Amsterdam 14
Brasília 14
Philadelphia 14
Belo Horizonte 13
Cairo 13
Cape Town 13
Charlotte 13
Istanbul 13
Melbourne 13
Mexico City 13
New Delhi 13
Salvador 13
Curitiba 12
Totale 10.079
Salva come PNG Salva come JPEG
Nome #
From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction 621
Differential Association of Sex Hormones with Metabolic Parameters and Body Composition in Men and Women from the United States 462
Is Switching from Oral Antidiabetic Therapy to Insulin Associated with an Increased Fracture Risk? 462
Exploring the landscape of steatotic liver disease in the general US population 441
Metabolic dysfunction-associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi-centre cross-sectional study 416
Resting Energy Expenditure in Obese Women with Primary Hypothyroidism and Appropriate Levothyroxine Replacement Therapy 350
Endocrinology and Metabolic Diseases (Including Diabetes) 349
Resting Whole Body Energy Metabolism in Class 3 Obesity; from Preserved Insulin Sensitivity to Overt Type 2 Diabetes 258
Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting 247
Screening of SLC2A1 in a large cohort of patients suspected for Glut1 deficiency syndrome: identification of novel variants and associated phenotypes 240
Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions 231
High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes 231
Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes 225
The Role of Natriuretic Peptides in the Management of Heart Failure with a Focus on the Patient with Diabetes 224
Adherence to antidiabetic drug therapy and reduction of fatal events in elderly frail patients 214
Seasonal variation in estimated cardiovascular risk in patients with type 2 diabetes 213
Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence 212
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes 209
Time trends in liver-related mortality in people with and without diabetes: Results from a population based study 201
Hepatitis C virus infection and diabetes: a complex bidirectional relationship 201
Prolonged Use of Proton Pump Inhibitors and Risk of Type 2 Diabetes: Results From a Large Population-Based Nested Case-Control Study 198
Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States 196
Preferences, Expectations and Attitudes on Basal Insulin from Patient–Physician–Payer Perspective: A Multi-stakeholder Survey by the Italian Diabetes Society (ITA4P Study) 194
Development of a new model of insulin sensitivity in patients with type 2 diabetes and association with mortality 194
Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications 193
Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD 192
Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment 190
Lack of awareness of liver organ damage in patients with type 2 diabetes 190
Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population 190
Setting up of a machine learning algorithm for the identification of severe liver fibrosis profile in the general US population cohort 189
Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes 189
Baseline TSH levels and short-term weight loss after different procedures of bariatric surgery 187
Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017–2018 National Health and Nutrition Examination Survey 186
Metabolic and psychological features are associated with weight loss 12 months after sleeve gastrectomy 182
Liver fibrosis, NT-ProBNP and mortality in patients with MASLD: a population-based cohort study 177
Authors' response to Guo, Wei et al. 176
NAIF: A novel artificial intelligence-based tool for accurate diagnosis of stage F3/F4 liver fibrosis in the general adult population, validated with three external datasets 176
NT-ProBNP and mortality across the spectrum of glucose tolerance in the general US population 173
Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories 173
Authors' reply to Zou et al 172
Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population 172
Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population 170
Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy 169
Impact of the duration of type 2 diabetes on the screening for nonal- coholic fatty liver disease and advanced fibrosis 169
Reliability of heart rate in reflecting cardiac sympathetic overdrive in type 2 diabetes mellitus 169
An unexpected bilateral mass after total thyroidectomy 168
Evaluating the Prognostic Value of the Triglyceride–Glucose Index in Different Populations: A Critical Analysis 166
Medication Use Before and After Different Bariatric Surgery Procedures: Results from a Population-Based Cohort Study 165
Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents 165
Hypercortisolism and altered glucose homeostasis in obese patients in the pre-bariatric surgery assessment 164
Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting 163
GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes 162
Hypercortisolism and altered glucose homeostasis in obese patients in the pre-bariatric surgery assessment 162
Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016 161
Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis 161
Adherence of systematic reviews to Cochrane RoB2 guidance was frequently poor: a meta epidemiological study 158
Risk stratification tools for heart failure in the diabetes clinic 157
Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: impact of the 2020 KDIGO clinical practice guidelines 157
Shaping the future of pediatric liver health: unraveling the impact of the new metabolic-associated fatty liver disease definition 155
Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes 151
Sex-related association of NAFLD and liver fibrosis with body fat distribution in the general US population 151
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease 150
Authors' reply to Shang et al. 150
Serum neurofilament light chain levels are associated with all-cause mortality in the general US population 149
Association between continuous glucose monitoring metrics and metabolic dysfunction-associated steatotic liver disease in adults with type 1 diabetes undergoing vibration-controlled transient elastography: a multicenter cross-sectional study 146
Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population 146
Steatotic Liver Disease Phenotypes in the United States: The Impact of Alcohol Consumption Assessment 143
Low 25 (OH) vitamin D levels are associated with increased prevalence of NAFLD and significant liver fibrosis 142
Diabetes mellitus is associated with higher serum neurofilament light chain levels in the general U.S. population 141
Glycated albumin is associated with all-cause and cardiovascular mortality among U.S. adults with and without diabetes: A retrospective cohort study 140
Visit-to-visit blood pressure variability in patients with type 2 diabetes with and without previous history of cardiovascular disease 140
NAFLD and liver fibrosis are not associated with reduced femoral bone mineral density in the general US population 139
Liver stiffness is associated with all-cause mortality in patients with NAFLD: A systematic review and meta-analysis 138
Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease 136
Readily Available Index of Insulin Sensitivity Is Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis in Patients with Type 2 Diabetes 134
Current type 2 diabetes, rather than previous gestational diabetes, is associated with liver disease in U.S. women 133
Resmetirom for the treatment of nonalcoholic steatohepatitis: Evaluating the robustness of available evidence 132
Reply [to: Use of FibroScan–AST Score to Stratify High-Risk Nonalcoholic Steatohepatitis in US...] 132
Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States 128
Reply to "Liver fibrosis assessed by transient elastography and albuminuria" 127
Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis 126
Global multi-stakeholder endorsement of the MAFLD definition 125
Comment on “An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD” 123
Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis 123
Twenty-year trends in heart failure among U.S. adults, 1999–2018: The growing impact of obesity and diabetes 121
Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes and association with micro- and macrovascular complications 119
The MAFLD‐MASLD debate: Does cardiovascular risk prediction define the winner? 118
Non-invasive scores of liver fibrosis in morbidly obese patients 117
Trends in prevalence of probable fibrotic nonalcoholic steatohepatitis in the United States, 1999-2016 113
Chronic Hepatitis B and MASLD: Growing Awareness and Unmet Clinical Needs 112
Advances in fibrosis biomarkers in nonalcoholic fatty liver disease 110
Control of Blood Glucose and Cardiovascular Risk Profile 108
Peripheral artery disease and all-cause and cardiovascular mortality in patients with NAFLD 105
Silent threats: how NAFLD and hypertension team up in young adults, and the role of sex 101
Soluble α-Klotho levels, glycemic control and renal function in US adults with type 2 diabetes 101
Prevalence of Noninvasively Detected Clinically Significant Portal Hypertension Among U.S. Adults With and Without Diabetes 101
Qualitative Properties of Circulating Fatty Acids Are Associated With MASLD: A Cross-Sectional Study From the NHANES Database 68
Effect of Weight Loss on Clinical Outcomes in Patients With Chronic Gastrointestinal and Liver Diseases 56
Assessing Europe's policy readiness to confront the MASLD/MASH public health threat 20
Totale 17.752
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.303
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.303
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022741 117 88 99 42 25 52 28 35 50 62 44 99
2022/20231.240 146 226 123 108 92 228 40 71 87 26 58 35
2023/20241.236 89 42 84 102 112 216 166 53 91 53 34 194
2024/20254.090 215 404 309 233 331 220 288 121 343 517 427 682
2025/20269.024 883 717 637 902 859 410 1.182 438 640 698 893 765
2026/2027172 172 0 0 0 0 0 0 0 0 0 0 0
Totale 17.752